Skip to main content

Investors & Media
- Overview
Careers
Contact Us

Home
Science
Patients & Caregivers
Medicines
Responsibility
Stories
About

- Home
- Science
  - Overview
  - Pipeline
  - Programs
    - Overview
    - KRAS Inhibitors
      - Overview
      - KRAS G12C Inhibitor
      - KRAS G12D Inhibitor
    - Sitravatinib
    - PRMT5
      Inhibitor
  - Clinical Trials
  - Presentations & Publications
- Patients & Caregivers
- Responsibility
- Stories
- About
- Investors & Media
  - Overview
- Careers
- Contact Us

Events &
Presentations

Overview

Overview

Upcoming Events

Archived Events

Selecting a year value will change the presentation content

Select year:

Featured Presentation

Contact Us

Investor Relations

Media Relations

media@mirati.com

Quick Links

SEC Filings
Investor FAQs
Information Request Form

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Mirati Therapeutics Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Mirati Therapeutics Inc. to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert Options *

News
Events & Presentations
Quarterly Reports
Annual Reports
SEC Filings

Unsubscribe

Email Alert Sign Up Confirmation

Facebook
Twitter
Linkedin

© Copyright - Mirati Therapeutics, Inc.

1-844-MIRATI-1 (1-844-647-2841)
info@mirati.com

Terms of Use
Privacy
Cookies
Purchase Order Terms

Expanded access
Community Guidelines

Powered By Q4 Inc. 5.104.0.1 (opens in new window)